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Background: Reports on common mutations in neuroendocrine tumors (NET) are rare and clonality of NET
metastases has not been investigated in this tumor entity yet. We selected one NET and the corresponding lymph
node and liver metastases as well as the derivative cell lines to screen for somatic mutations in the primary NET
and to track the fate of genetic changes during metastasis and in vitro progression.
Results: Applying microarray based sequence capture resequencing including 4,935 Exons from of 203
cancer-associated genes and high-resolution copy number and genotype analysis identified multiple somatic
mutations in the primary NET, affecting BRCA2, CTNNB1, ERCC5, HNF1A, KIT, MLL, RB1, ROS1, SMAD4, and TP53. All
mutations were confirmed in the patients’ lymph node and liver metastasis tissue as well as early cell line passages.
In contrast to the tumor derived cell line, higher passages of the metastases derived cell lines lacked somatic
mutations and chromosomal alterations, while expression of the classical NET marker serotonin was maintained.
Conclusion: Our study reveals that both metastases have evolved from the same pair of genetically differing NET
cell clones. In both metastases, the in vivo dominating “mutant” tumor cell clone has undergone negative selection
in vitro being replaced by the “non-mutant” tumor cell population. This is the first report of a bi-clonal origin of NET
derived metastases, indicating selective advantage of interclonal cooperation during metastasis. In addition, this
study underscores the importance to monitor cell line integrity using high-resolution genome analysis tools.
Keywords: Neuroendocrine tumors, Clonality of metastases, Somatic mutationsBackground
Tumour metastasis is a multistage process in which malig-
nant cells spread from the initial tumour to colonize the
same or distant organs [1]. Sequential events during metas-
tasis involve local invasion, intravasation, and survival in
the circularization, extravasation and colonization of the
host organ. An important variable is the temporal course
of metastasis. Whereas breast cancer recurrences are often
detected following decades of remission, lung cancers es-
tablish distant metastases within months of diagnosis [2-4].
Apparently, the capacity of cancer cells to infiltrate distinct
organs and to develop macrometastases does not coincide.
It is hypothesized, that during this period of metastatic la-
tency disseminated cancer cells acquire the ability to* Correspondence: Christian.guelly@medunigraz.at
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reproduction in any medium, provided the orcolonize the host organ [1]. Among other factors like
immunosurveillance, switches of transcriptional pathways
and programmes, the local microenvironment is consid-
ered a critical determinant of metastatic outgrowth. During
the latency period a local malignant (co)evolution of the
disseminated cancer cell and/or the seeded microenviron-
ment might be required for effective colonization and
metastatic outgrowth. To date dissemination and meta-
static outgrowth has mainly been attributed to clonally
derived cancer cells. Even in advanced genetically heteroge-
neous primary tumors metastases appear to be of clonal
origin [5,6], although concepts of interclonal cooperativity
have been considered and tested in model systems [7-9].
In a recent report, [10] massive parallel DNA sequence
analysis revealed statistical evidence for the multiclonal
origin of breast cancer metastases. By comparison of the
mutation spectrum of a breast cancer patient’s primary
and secondary tumors, the prevalence of specific muta-
tions was found significantly decreased or increasedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patient’s metastases have been formed by at least three
different cell clones.
We have chosen three recently described [11] novel
cell lines established from a metastatic midgut (terminal
ileum) neuroendocrine tumor (NET) of the same patient
together with the corresponding original tissue samples:
1) P-STS, a cell line established from the primary tumor
(P-Tu), 2) L-STS, from a lymph node metastasis, and 3)
H-STS, a cell line established from a liver metastasis, to
screen for mutations in the P-Tu and to explore the evo-
lution of somatic mutations and corresponding cell
population kinetics during in vitro cultivation.
Results
Targeted resequencing
Using the hg18 reference sequence (ucsc genome db)
we have designed a custom sequence capture array
(NimbleGen 385 k technology) including 4,935 Exons
from 203 cancer associated genes based on the informa-
tion available via the Cancer Gene Census (http://www.
sanger.ac.uk/genetics/CGP/Census/) [12] and 16 collagen
genes, comprising a total of 1.4 Mb of genomic information
for enrichment and subsequent 454 GS FLX Titanium
based parallel re-sequencing (Additional file 1: Table S1).
Primarily, only cancer-associated genes known for and
characterised by missense mutations, stop-mutations, small
and large in/del mutations as well as frame-shift mutations
were included in the design of the capture array.
Sequencing of ~ 70 Mb of target-enriched genomic
information per sample (Table 1 A) was sufficient to
achieve an average of > 25-fold coverage of the target
region. 63-79% of the reads mapped to the target region
with > 80% of target bases covered at least 5-fold
(Table 1 A). 4,489 high-confidence sequence variants
were detected for the P-Tu sample using the standard
GS Reference Mapper tool (UCSC hg18 built, SNPdb
built130), with 3,961 of these representing known var-
iants. 280 variants were detected within the exonic
sequences. 27 of these variants were novel; 24 thereof
non-synonymous. (Table 1 B and Additional file 1: Table
S2 A). We could identify four genes (SDHB, COL4A3,
LIFR, HIST1H2BA) with known mutations observed in all
samples as can be seen in the Venn diagram (Figure 1).
The fraction of non-synonymous to synonymous sequence
variants among the newly identified variants was dispro-
portionately higher (> 5-fold) compared to the ratio within
the known variants (Table 1 B) indicating a substantial
fraction of these variants to be of somatic origin. Although
all samples were sequenced to approximately the same
coverage, the L-STS p49 and H-STS p42 cell lines lacked
the variants identified in the P-Tu and did not show sam-
ple specific variants (Table 1 B and Additional file 1: Table
S2 c and d). A high level of sequence capture efficiencyand reproducibility among the processed samples is
shown for a representative locus (BRCA2; Additional file
1: Figure S1).
Sanger sequencing of BRCA2, CTNNB1, ERCC5, HNF1A,
KIT, MLL, RB1, ROS1, and SMAD4
Six of the novel heterozygous missense variants (BRCA2,
ERCC5, KIT, MLL, SMAD4, and ROS1) and three frame-
shift sequence variants of RB1, HNF1A and CTNNB1
identified in the P-Tu sample were selected for further
investigation (Table 1 C). None of these mutations was
detectable in blood derived DNA of the same patient by
Sanger sequencing proving the somatic origin of the
mutations. All variants were heterozygous and detectable
in both metastases (9/9 variants) and the corresponding
cell lines H-STS (9/9) and P-STS (9/9) at lower passages
(passage 7 for H-STS, and 14 for P-STS; Table 2)
whereas the L-STS at passage 9 has already lost the mu-
tant alleles and displayed only reference/wild-type allele
information (Table 2) for all nine investigated markers.
None of these sequence variants initially detected in the
P-Tu tissue and in cell line P-STS was found in the me-
tastasis derived cell lines L-STS and H-STS at higher
passages (passages 41, 49, and 42 respectively).
High-resolution melting curve analysis
To evaluate, whether the sequence variants might still
occur albeit at lower frequency eventually in form of a
minor (background) cell population, we implemented
high-resolution melting curve analysis for MLL (mis-
sense variant) and RB1 (frameshift mutation). Using
mutation specific HRM assays with a 10% minor vari-
ant detection limit, we confirmed heterozygosity of the
variants in the P-Tu sample as well as the higher
passages of P-STS sample and the absence of a ≥ 10%
subpopulation in the L-STS p49 and H-STS p42 cell
lines (Additional file 1: Figure S2).
Sequencing of TP53 variants
Two TP53 sequence variants (SNP rs1042522, p.R72P
and mutation c.C817T encoding p.R273C; Table 1 C)
were identified in the P-Tu sample, whereas the data
from the P-STS p41 indicated homozygous mutant TP53
sequence information (100% of the reads; total of 28
reads). The TP53 c.C817T mutant was not detectable in
L-STS p49 and H-STS p42 by next-generation sequen-
cing, revealing only wild-type sequence reads. The
known TP53 SNP rs1042522 was confirmed heterozy-
gous in the blood DNA sample, whereas the c.C817T
mutation was not detectable in this reference DNA, val-
idating the somatic origin of the known TP53 mutation.
Accordingly, Sanger sequencing confirmed heterozygos-
ity for both TP53 sequence variants in the P-Tu and the
metastatic tissues (liver and lymph node). As observed
Table 1 Statistics on sequence capture based resequencing
A)
p-TU P-STS -P41 H-STS -P42 L-STS -P49
Total number of reads 272,728 270,044 256,619 268,969
Numb. of mapped reads 262,773 (96.35%) 259,781 (96.20%) 247,300 (96.37%) 258,908 (96.26%)
NumUniqueInRegions
(reads within target region
184,206 (72.08%) 200,711 (78.60%) 192,918 (79.38%) 160,272 (63.75%)
Average coverage ~29.3-fold ~31.9-fold ~30.7-FOLD ~25.5-FOLD
% target bases covered ≥ 5-fold >89% >86% >81% >82%
B)
p-TU P-STS -P41 H-STS -P42 L-STS -P49
HC Diffs (total) 4489 3756 3541 4631
HC Diffs (known) 3961 3372 3163 3907
HC DIffs (within cds) 280 251 206 213
novel or pathogenic (in coding seq.) 27 26 6 7
non-synonymous 24 19 5 6
synonymous 3 7 1 1
knowing (in coding seq.) 253 225 200 206
non-synonymous 97 80 77 77
synonymous 156 145 123 129
C)
GeneID Status Mut. type Nucleotide AA Refseq ID Chr. Position
BRCA2 unknown missense c.C1783T H595Y NM_000059.3 13q 31805398
ERCC5 unknown missense c.T266C V89A NM_000123.2 13q 102304109
KIT unknown missense c.A1606C M536L NM_000222.1 4q 55288206
MLL unknown missense c.C11305T H3769V NM_005933.2 11q 117895710
ROS1 unknown missense c.G625A D209N NM_002944.2 6q 117824925
SMAD4 unknown missense c.G290A R97H NM_005359.5 18q 46829094
SDHB unknown missense cC98T A33L Nm_003000.2 1p 17243945
HNF1A unknown frameshift c.872_873insC p.G292fs*25 NM_000545.4 12q 119916507
RB1 known missense c.211_213insAG p.A74fs*3 NM_000321.2 13q 47779500
TP53 known missense c.C817T R273C NM_000546.4 17q 7517846
TP53 rs1042522 missense c.C215G R72P NM_000546.4 17q 7520197
HNF1A rs56348580 synon. cG864C G288G NM_000545.4 12q 119916500
KIAA1549 rs59985563 missense cA1090G T364A NM_001164665.1 7q 138253822
KIAA1549 rs61734132 missense cC1940G S647C NM_00164665.1 7q 138252972
Sequencing statistics (A) and target region related detection of High Confidence Differences (B). C: Selected sequence variants (known mutations, unknown
variants and SNPs) further pursued by complementary methods. Chromosomal positions according to Ensembl database release 54 from May 2009.
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L-STS p49 cell lines exhibited a loss of the mutant allele
information at higher passages and in H-STS p7. In con-
trast, P-STS p41 exclusively exhibited the TP53 sequence
variant at higher passages, which was a result of a copy
neutral loss of heterozygosity after passage 14, as deter-
mined by complementary methods (e.g. microarray based
CNV analysis; Additional file 1: Table S4). Complete Sub-
mission SRA055939; pTU SRR521279; hSTS SRR521655;
pSTS SRR521658; lSTS SRR521659.Chromosomal copy number (CN) analysis using
Affymetrix 6.0 CNV/SNP arrays
To evaluate, whether chromosomal imbalances (espe-
cially loss of heterozygosity; LOH) might have contribu-
ted to the selective loss of the variant alleles we
performed copy number (CN) and genotype analysis
using Affymetrix 6.0CNV/SNP Arrays (Additional file 1:
Table S4). We did not observe any CN alterations for
the L-STS p49 and the H-STS p42 cell lines. The pri-
mary NET (P-Tu) displayed a single copy neutral LOH
Figure 1 Venn diagram of P-STS, H-STS, L-STS: Four genes
(SDHB, COL4A3, LIFR, HIST1H2BA) with a common mutation
over all screened samples could be identified.
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gain of chromosome arms 1p and 17q-p11 and loss of
3p26.3-p11.2, 4q35.1-qter, 11q23.2-q23.3 and 20p13-
p12.1 (Additional file 1: Figure S3). Both metastases
tissues (L-Met and H-Met) displayed the same copy neu-
tral LOH at chr.3 as the P-Tu, without the indication of
further chromosomal alterations. CN data are summarized
in Additional file 1: Table S4. In-depth analysis of the CN
probes and genotypes at the genetic loci of BRCA2,
ERCC5, KIT, MLL, SMAD4, ROS1, RB1, TP53 and
HNF1A revealed unchanged CN (n = 2) with interspersed
heterozygous genotypes (Additional file 1: Figure S4 a-i). In
contrast, the expected loss-of-heterozygosity (LOH) at the
TP53 locus of the P-STS sample turned out to be a copy
number neutral LOH, resulting from an early loss of the
wild-type allele followed by re-duplication of the mutant
allele (Additional file 1: Figure S4 e) (complete array data
are accessible trough GEO Series accession number GEO
Accession Nummer: GSE39371; GSM966942 primary
tumor p-TU; GSM966943 cell line H-STS; GSM966944
cell line L-STS; GSM966945 cell line P-STS).
Immunofluorescence analysis for serotonin (5-HT) on a
confocal scanning microscope
Immunocytochemical characterization in former studies
[11] showed an expression of pancytokeratin, cytokeratins
7, 8, 18 and 19, serotonin (5-HT), NSE, CD56, protein
gene product 9.5 (PGP9.5), calcitonin, synaptophysin, and
gastrin-releasing factor in the P-STS cell line. The L-STS
cell line was characterized for positive immunoreactivity
with cytokeratin 8/18 (CK8/18) and PGP 9.5. The H-STS
cell line showed a positive immunocytochemical reactivity
for chomogranin (CG), serotonin (5-HT), PGP9.5 and
CK8/18. The NET cell status at higher cell passages wasconfirmed by immunodetection of serotonin expression
by confocal laser scanning microscopy (Figure 2 upper
panel). Furthermore, unspecific binding was excluded by
preadsorption with 1 mM serotonin creatinine sulphate
complex which resulted in a suppression of the staining
(Figure 2 lower panel).
Discussion
While chromosomal aberrations are frequently found in
midgut NETs [13-15], reports on the observation of fre-
quent gene mutations (SDHD, K-ras) are rare. By virtue
of sequence capture based high-throughput sequencing
targeting 203 known cancer associated genes; we have
identified multiple de-novo somatic mutations in a pri-
mary midgut NET (P-Tu). Mutations affect genes
involved in the regulation of the cell cycle (TP53 and
RB1), apoptosis, senescence and DNA repair (BRCA2,
ERCC5 and TP53), transcriptional regulation (MLL,
SMAD4 and HNF1A) and cell signalling (CTNNB1, KIT
and ROS1). Whereas these tumor-specific mutations
were conserved in the patient’s lymph node- and liver
metastases, the heterozygous sequence variants were lost
in metastases derived cell lines (H-STS and L-STS), indi-
cating a lack of selective pressure to maintain the muta-
tions (probability of < 0.1% for the random loss of 10/10
mutations) during in vitro-cultivation. Notwithstanding
several prominent mutations in the DNA repair genes,
no increase in the number of mutations or CNVs was
observed in the L-STS and H-STS, whereas the P-STS
acquired multiple chromosomal alterations during
in vitro cultivation not evident in the P-Tu.
The only chromosomal alteration observed for the P-
Tu and the metastases is a copy neutral LOH on
chromosome 3p21-p26. Among the DNA mismatch re-
pair gene MLH1 (3p21.3-p23) and the DNA repair gene
XPC (3p25.23), which is frequently found mutated in
Xeroderma pigmentosum syndrome type C [16], this
locus contains the VHL (von Hippel-Lindau) tumor sup-
pressor gene. Germline mutations of VHL have been
reported in patients with the von Hippel-Lindau disease,
a familial cancer syndrome. All three genes were covered
by the sequence capture array and sequenced to suffi-
cient depth to identify eventually occurring variants in
coding sequences. Nonetheless, no exonic sequence var-
iants were observed for these genes, although any var-
iants affecting gene regulatory regions might be missed
by our enrichment approach.
The P-STS cell line acquired several aberrations fre-
quently observed in lung and midgut NETs (loss of
chromosome 3p, gain of 17q and mutation of TP53)
[13]. Reduplication of one parental allele coinciding with
loss of the other allele inevitably leads to a copy neutral
LOH indicated by homozygosity and a CN of 2 at the re-
spective region. We observed this event at the TP53
Table 2 Difference confirmation by sanger sequencing
somatic variations missense MLL:NM_005933 P-TU het C/T H-STS het C/T L-STS het C/T
cC11305T (H3769V) P-STS P14 het C/T H-STS P7 het C/T L-STS P9 hom C (wt)
P-STS P41 het C/T H-STS P42 hom C (wt) L-STS P49 hom C (wt)
BRCA2: NM_000059 P-TU het C/T H-STS het C/T L-STS het C/T
cC1783T (H595Y) P-STS P14 het C/T H-STS P7 het C/T L-STS P9 hom C (wt)
P-STS P41 het C/T H-STS P42 hom C (wt) L-STS P49 hom C (wt)
ERCC5: NM_000123 P-TU het T/C H-STS het T/C L-STS het C/T
cT266C (V89A) P-STS P14 het T/C H-STS P7 het T/C L-STS P9 hom T (wt)
P-STS P41 het T/C H-STS P42 hom T (wt) L-STS P49 hom T (wt)
KIT: NM_000222 P-TU het A/C H-STS het A/C L-STS het A/C
cA1606C (M536L) P-STS P14 het A/C H-STS P7 het A/C L-STS P9 hom A (wt)
P-STS P41 het A/C H-STS P42 hom A (wt) L-STS P49 hom A (wt)
TP53: NM_000546 P-TU het C/T H-STS het C/T L-STS het C/T
cC817T (R273C) P-STS P14 het C/T H-STS P7 het C/T L-STS P9 hom C (wt)
P-STS P41 het C/T H-STS P42 hom C (wt) L-STS P49 hom C (wt)
SMAD4: NM_005359 P-TU het G/A H-STS het G/A L-STS het G/A
cG290A (R97H) P-STS P14 het G/A H-STS P7 het G/A L-STS P9 hom G (wt)
P-STS P41 het G/A H-STS P42 hom G (wt) L-STS P49 hom G (wt)
ROS1: NM_002944 P-TU het G/A H-STS het G/A L-STS het G/A
P-STS P14 het G/A H-STS P7 het G/A L-STS P9 hom G (wt)
P-STS P41 het G/A H-STS P42 hom G (wt) L-STS P49 hom G (wt)
frame
shift
HNF1A: NM_00545.4 P-TU het C ins het C ins L-STS het C ins
P-STS P14 het C ins het C ins L-STS P9 wt
P-STS P41 het C ins wt L-STS P49 wt
CTBBB1: NM_001098209.1 P-TU het GTT del H-STS het GTT del L-STS het GTT del
P-STS P14 het GTT del H-STS P7 het GTT del L-STS P9 wt
P-STS P41 hom GTT del H-STS P42 wt L-STS P49 wt
germline transmited variants SNP HNF1A: NM_000545.4 P-TU hom C H-STS hom C L-STS hom C
cG864C (G288G) P-STS P14 hom C H-STS P7 hom C L-STS P9 hom C
rs 56348580 P-STS P41 hom C H-STS P42 hom C L-STS P49 hom C
TP53: NM_000546 P-TU het C/G H-STS het C/G L-STS het C/G
cC215G (P72R) P-STS P14 het C/G H-STS P7 het C/G L-STS P9 het C/G
P-STS P41 homG H-STS P42 het C/G L-STS P49 het C/G
KIAA1549: NM_001164665.1 P-TU homG H-STS homG L-STS homG
cA1090G (T364A) P-STS P14 homG H-STS P7 homG L-STS P9 homG
rs59985563 P-STS P41 homG H-STS P42 homG L-STS P49 homG
KIAA1549: NM_001164665.1 P-TU homG H-STS homG L-STS homG
cC1940G (S647C) P-STS P14 homG H-STS P7 homG L-STS P9 homG
rs61734132 P-STS P41 homG H-STS P42 homG L-STS P49 homG
missense SDHB: NM_003000.2 P-TU het C/T H-STS het C/T L-STS het C/T
cC98T (A33L) P-STS P14 het C/T H-STS P7 het C/T L-STS P9 het C/T
P-STS P41 het C/T H-STS P42 het C/T L-STS P49 het C/T
NOTCH1: NM_017617.3 P-TU het G/T H-STS het G/T L-STS het G/T
cG5457T (E1818D) P-STS P14 het G/T H-STS P7 het G/T L-STS P9 het G/T
P-STS P41 het G/T H-STS P42 het G/T L-STS P49 het G/T
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Table 2 Difference confirmation by sanger sequencing (Continued)
MYC: NM_002467.4 P-TU het T/C H-STS het T/C L-STS het T/C
cT64C (F22L) P-STS P14 het T/C H-STS P7 het T/C L-STS P9 het T/C
P-STS P41 het T/C H-STS P42 het T/C L-STS P49 het T/C
Sequencing results as determined for the selected missense, frame-shift and SNPs variants in the primary tumor (P-TU), the metastatic tissues (H-STS and L-STS)
and early and late passages of the respective tissue-derived cell lines. Het: heterozygous genotype; Hom: homozygous genotype; wt: wild-type e.g. same seq.
information as observed for blood DNA.
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line. It has been shown in a previous study that tumori-
genicity of both metastases derived cell lines (20% and
60% for L-STS p45 and H-STS p40) in SCID mice was
substantially decreased compared to the P-STS p25
(100% tumorigenicity) cell line [11]. Poor survival and
increased aggressiveness in lung NET patients have been
attributed to mutations in the TP53 gene [17], which
might be mirrored by the differing tumorigenicity of the
cell lines in SCID mice and the concordant bi-allelic de-
letion of TP53 in the P-STS cell line.
Heterozygosity at the BRCA2, CTNNB1, MLL,
SMAD4, ERCC5, RB1 and KIT chromosomal loci and a
CN of 2 indicate that another mechanism must have
lead to the loss of the mutations during in vitro cultiva-
tion. Maintenance of serotonin expression in the L-STS
and the H-STS throughout cell passaging proves a clas-
sical NET characteristic [18] of the cell lines. It is highly
unlikely that all the DNA alterations observed in the pri-
mary tissues were selectively repaired during in vitro cell
expansion almost in parallel (in early passages) and
indepently in both cell lines (L-STS and H-STS). WeFigure 2 Immunodetection of serotonin expression at higher cell pas
neuroendocrine tumor cell line was used as positive control (data not show
P-STS, pa L-STS, pa H-STS) was done to obviate unspecific binding.presume that a minor NET cell population bearing none
of the mutant alleles, which must have already been
present during metastasis, has overgrown and replaced
the initially dominating mutant H-STS and L-STS cell
lines in parallel. This hypothesis implies the intriguing
fact that metastasis formation and/or outgrowth must
have involved a multiclonal complex comprising at least
two different NET cell populations. This could have hap-
pened in two ways, either by dissemination of a multicel-
lular complex consisting of at least two genotypically
different NET subclones or by a stepwise process where
the newly established metastasis has attracted other circu-
lating tumor cells to associate. It is likely that the reported
different tumorigenic properties in SCID mice are directly
linked their genomic alterations. Additionally, the parallel
finding of metastatic bi-clonality might indicate com-
mensal biological tasks during metastases formation. Vari-
ous biological effects might underlie this interdependence.
A non-mutant (or less mutant) tumor cell population will
be less immunogenic thereby protecting early metastatic
outgrowth. Functional studies deploying mixtures of clon-
ally expanded metastases and/or primary tumor derivedsages (P-STS P49, L-STS P42 and H-STS P41). The KRJ
n). Preadsorption (pa) with serotonin creatinine sulphate complex (pa
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to further investigate the biological principles in an appro-
priate environment.
Conclusion
In our study, we demonstrate the bi-clonal origin of two
metastases of a NET patient using DNA-enrichment fol-
lowed by massive parallel resequencing and based on in-
vitro selection identify and genetically characterize the
clonal partners. In our discussion, we propose a model of
clonal interdependence during metastases formation as the
underlying biological mechanism. Nevertheless, interclonal
dependence during metastasis formation might offer an-
other avenue for the development of anti-cancer strategies.
Methods
Cell lines and cultivation
P-STS cells were cultured in Ham´s F12:M199 (PAA La-
boratories, Pasching, Austria) (1:1) supplemented with
10% FBS (PAA). KRJ-I [16] were cultured in Ham’s F12
medium. The two metastatic cell lines L-STS and H-STS
were cultured in serum free Quantum 263 Complete
Medium (PAA). All cells were kept in a 5% CO2 atmos-
phere at 37°C. An adequate review of the immunocyto-
chemical analysis for NET markers especially in the low
passages was done previously (Pfragner et al. 2009). Cell
cultures were periodically checked for mycoplasma con-
tamination. During this study, cell line batches from low
passage (< 15) and high passages (> 15) were used.
Confocal laser scanning microscopy
Suspensions of P-STS, L-STS, and H-STS were analyzed
for serotonin (5_HT) immunoreactivity. The KRJ-I NET
cell line served as positive control (data not shown).
Negative controls were incubated in buffer instead of the
primary anti-serotonin antibody. The primary anti-
serotonin antibody was preadsorbed at a dilution of
1:2.000 in 1 mM serotonin creatinine sulphate complex
(Sigma, Vienna, Austria) for 1h at 37°C. For immuno-
fluorescence, cells were fixed in 2% paraformaldehyde
for 15 min, incubated in.blocking solution for 30 min at
RT and incubated for 16–24 hours at 4°C with the pri-
mary antibody (polyclonal rabbit-anti-human serotonin;
Acris Immunostar, Hudson, WI). After incubation with
goat-anti-rabbit-Cy3 antibody (Jackson, Suffolk, UK) for
2 h at RT in the dark the cells were analysed on a con-
focal laser scanning microscope (Leica TCS SP2; Leica
Lasertechnik GmbH, Heidelberg, Germany). Scanning
parameters were adjusted for each cell type using its
pre-adsorption control.
Sequence capture array design
A custom tiling NimbleGen 385 k sequence capture array
targeting the exonic sequences (n = 4,935) of 203 cancerassociated genes and 16 collagen genes were designed and
manufactured by Roche NimbleGen. The array was
designed using NimbleGen’s standard 15-mer frequency
masking to minimize repeat content within capture
probes. The probe spacing, tiling overlap, and probe
length were determined by NimbleGen using proprietary
algorithms. A GFF- or BED-formatted file (Additional file
2 and 3) allowing visualization of the tiled intervals by the
Genome Browser (http://genome.ucsc.edu/).
Sequence capture library construction
Genomic DNA (20 μg per sample) isolated from the
snap-frozen primary tumor sample and the three corre-
sponding cell lines (P-STS, H-STS and L-STS) was
processed into a capture library according to the manu-
facturers protocol (Additional file 1: Procedure S1).
Capture array handling
Hybridization was performed using microarrays merged
with X1 mixer on the NimbleGen Hybridization System
for 3 days at 42°C following the manufacturer’s recom-
mended conditions (Additional file 1: Procedures S2).
Quantitative PCR (SYBR-Green based; LC480 instru-
ment) using four internal NimbleGen control loci (NSC-
0237, NSC-0247, NSC-0268, NSC-0272) was performed
to estimate relative fold-enrichment (data not shown).
GS FLX sequencing
The amplified capture libraries were processed into sequen-
cing libraries for the 454 GS-FLX using the Shotgun DNA
Titanium Library Construction Kit and low-molecular-
weight DNA (without the nebulisation step) protocols (454
Life Sciences, Branford, CT) according to the manufac-
turer’s recommended conditions. Each captured sample li-
brary was sequenced using a quarter of a Titanium
PicoTiterplate (70x75) run on the GS-FLX platform.
Data analysis - Variant detection and annotation
High Confidence Differences were calculated using the GS
Reference Mapper assembly package (version 2.0.00.20;
Roche Diagnostics) and hg18 reference sequence and
SNPdb built 130 (Additional file 1: Procedures S3).
Sanger sequencing
Sequence variants observed by NGS sequencing were re-
evaluated by Sanger sequencing. PCR products were
purified using Nucleo FastW (Macherey-Nagel, Düren,
Gemany) clean up PCR plates according to the manufac-
turer´s protocol. Following purification, capillary se-
quencing reactions were performed using Applied
Biosystems BigDye Terminator v3.1 Ready Reaction
Cycle Sequencing Kit (Foster City, CA). Sequencing
reactions were purified using Sigma Spin Post Reaction
Clean-up Plates (Sigma-Aldrich, Austria) and run on an
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ABI SeqScape v2.5 software (Applied Biosystems).High resolution melting curve analysis
High Resolution Melting Curve analysis for variant posi-
tions in RB1 exon 2 and MLL exon 32 mutations was
performed using a LightCycler 480 system (Roche
Diagnostics, Penzberg, Germany). Primers were designed
using primer3 software to span the positions of interest
with product sizes of 134 bp for RB1 and 185 bp for
MLL. The 20 μl reaction mix for PCR amplification con-
tained 20 ng genomic template DNA, 10 μl of LightCy-
cler480 High Resolution Master Mix (Roche Diagnostics,
Penzberg, Germany), 10 μM of each primer and MgCl2
in a final concentration of 2.5 mM. The reaction condi-
tion included a pre-incubation step at 95°C for 10 min
for the activation of the polymerase, followed by 45
cycles of 95°C for 10 s, 58°C for 15 s and 72°C for 15 s.
A melting pre-hold step was included to ensure that all
PCR products have re-associated and encourage hetero-
duplex formation. The melting interval ranged from
65°C to 95°C and increased at 1°C per second with 35
acquisitions per degree. Normalized, temperature-shifted
melting curves carrying sequence variation were analyzed
using the automated grouping functionality provided by
the LightCycler480 GeneScanning 1.5 Software (Roche
Diagnostics, Penzberg, Germany).Affymetrix SNP 6.0 array processing and analysis
Affymetrix GeneChip Human Mapping SNP 6.0 arrays
were performed as described in the Genome-Wide
Human SNP Nsp/Sty 6.0 User Guide (Affymetrix Inc.,
Santa Clara, CA, USA). Detailed information: Additional
file 1: Procedures S4.
SNP 6.0 data were imported and normalized using the
Genotyping Console 4.0 program default settings. All sam-
ples passing QC criteria were subsequently genotyped
using the Birdseed (v2) algorithm. We used 60 raw Hap-
Map data generated with the Affymetrix Genome-Wide
Human SNP Array 6.0 as reference. Data were obtained
from Affymetrix (Affymetrix, Santa Clara, CA) web site
and used for normalization.Additional files
Additional file 1: Molecular evidence for the bi-clonal origin of
neuroendocrine tumor.
Additional file 2: BED File.
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